> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – November 2015

Loading EJC News Focus video

Immunotherapy: the future

Immunotherapy is at a strategic point, according to Caroline Robert (Gustave Roussy, Paris). Speaking at the opening plenary session of the European Cancer Congress (25–29 September 2015), she said that future developments will come from the fields of genomics and immunotherapy – and others – working together.

The tumours with the highest load of somatic mutations, such as melanoma and lung cancers, may be the ones that present most new antigens to the immune system, she said. So the cancers which have been most difficult to treat may in the end respond best to immunotherapy.

In this EJC News Focus, Caroline Robert explains more about the science and its implications to Helen Saul.